Baxdela (delafloxacin)

Baxdela, containing the active ingredient delafloxacin, is a fluoroquinolone antibiotic used to treat serious bacterial skin infections and community-acquired bacterial pneumonia. It was developed to address resistant strains of bacteria, including MRSA, providing a critical tool in modern clinical settings for managing acute infections.

The medication was originally developed and commercialized by Melinta Therapeutics, a company specialized in the discovery and development of novel anti-infectives. The brand represents a significant advancement in antimicrobial therapy, designed for both intravenous and oral administration to allow for flexible patient care.

Today, the brand remains under the stewardship of Melinta Therapeutics, which operates as a portfolio company of Deerfield Management. While the active pharmaceutical ingredients and final dosage forms are primarily manufactured in the United States to serve the high-demand medical market, distribution and secondary manufacturing partnerships may exist globally to support healthcare providers in various regions.